Related Experiment Videos
Experimental and modelling studies on the DNA cleavage by elsamicin A
A Párraga1, M Orozco, J Portugal
1Departamento de Bioquímica y Fisiología, Universidad de Barcelona, Facultad de Química, Spain.
European Journal of Biochemistry
|September 1, 1992
Summary
Elsamicin A, an anticancer antibiotic, cleaves DNA by producing superoxide radicals. Its unique mechanism, involving the chartarin aglycone, differs from quinone-based anticancer drugs.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Elsamicin A is an antitumour antibiotic with DNA-cleaving properties.
- The mechanism of DNA cleavage by elsamicin A, particularly the role of free radicals, requires elucidation.
Purpose of the Study:
- To analyze the DNA-cleaving ability of elsamicin A using experimental and theoretical methods.
- To investigate the involvement of free radicals and the redox properties of elsamicin A in DNA breakage.
Main Methods:
- Experimental analysis of DNA cleavage in the presence of ferrous ions and reducing agents.
- Inhibition studies using superoxide dismutase and catalase.
- Theoretical quantum-mechanical studies to determine redox properties and radical generation.
Main Results:
- Elsamicin A induces DNA breakage in the presence of ferrous ions and reducing agents.
- Superoxide dismutase and catalase partially inhibit DNA cleavage, suggesting free radical involvement.
- Theoretical studies confirm elsamicin A acts as a catalyst for superoxide radical production.
Conclusions:
- The chartarin aglycone moiety of elsamicin A is involved in free radical production leading to DNA cleavage.
- Elsamicin A's oxidation/reduction mechanism differs from quinone-based anticancer drugs.
- Elsamicin A functions as a catalyst in generating superoxide radicals for DNA breakage.